Pimitespib, an HSP90 inhibitor, augments nifuroxazide-induced disruption in the IL-6/STAT3/HIF-1α autocrine loop in rats with bleomycin-challenged lungs: Evolutionary perspective in managing pulmonary fibrosis
JavaScript is disabled for your browser. Some features of this site may not work without it.
Pimitespib, an HSP90 inhibitor, augments nifuroxazide-induced disruption in the IL-6/STAT3/HIF-1α autocrine loop in rats with bleomycin-challenged lungs: Evolutionary perspective in managing pulmonary fibrosis
El-Kashef, Dalia H; Youssef, Mahmoud E; Nasr, Mohamed; Alrouji, Mohammed; Alhajlah, Sharif; AlOmeirf, Othman; El Adle Khalaf, Noura; Abdel Ghaffar, Dalia M; Jamil, Lubna; Abdel-Nasser, Zeinab M; Ibrahim, Samar; Abdeldaiem, Mahmoud Said Ibrahim; Donia, Sally S; Mohammed, Osama A; Morsy, Nesreen Elsayed; Shata, Ahmed; Saber, Sameh
Idiopathic pulmonary fibrosis is a fatal lung disorder in which the etiology and pathogenesis are still unobvious.
Effective treatments are urgently needed considering that lung transplantation is the only treatment that could
improve outcomes. This study aimed to investigate the therapeutic significance of the dual administration of
pimitespib, an HSP90 inhibitor, and nifuroxazide, a STAT3 inhibitor, against bleomycin-induced pulmonary
